The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, awarded a $352,275 Project Grant to the Regents of the University of Minnesota to conduct research on targeting tumor cell mitochondria for the prevention and treatment of lung cancer. The project aims to assess the safety and efficacy of a mitochondria-targeted metformin analog called MITOMET in suppressing the malignant progression of lung tumors with co-occurring KRAS and LKB1 mutations, and to determine if MITOMET can sensitize these tumors to immunotherapy. The university will also compare the tumor propagating potential of different cancer cell subpopulations and assess the impact of MITOMET and/or immunotherapy on these cell types. The project period runs from January 1, 2025 to December 31, 2029.
Generated 2/25/25, 3:55 AM